Literature DB >> 22728872

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.

Toni Urbanik1, Regina Johanna Boger, Thomas Longerich, Katharina Becker, Karl Roland Ehrenberg, Nadine Hövelmeyer, Matthias Hahn, Marcus Schuchmann, Dirk Jäger, Ari Waisman, Marcus Alexander Wörns, Henning Schulze-Bergkamen.   

Abstract

BACKGROUND & AIMS: CYLD is a tumor suppressor gene that is mutated in familial cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. Reduced CYLD expression has been observed in other tumor entities, including hepatocellular carcinoma. In the present study, we analyzed the role of CYLD in liver homeostasis and hepatocarcinogenesis in vivo.
METHODS: Mice with liver-specific deletion of CYLDexon7/8 (CYLD(FF)xAlbCre) were generated. Liver tissues were histologically analyzed and oval cell activation was investigated. Hepatocarcinogenesis was induced by diethylnitrosamine/phenobarbital (DEN/PB). Microarray expression profiling of livers was performed in untreated as well as DEN/PB-treated mice. NF-κB signaling was assessed by ELISA, quantitative real-time PCR, and Western blotting.
RESULTS: CYLD(FF)xAlbCre hepatocytes and cholangiocytes did not express full-length CYLD (FL-CYLD) protein but showed increased expression of the naturally occurring short-CYLD splice variant (s-CYLD). CYLD(FF)xAlbCre mice exhibited a prominent biliary phenotype with ductular reaction and biliary-type fibrosis. In addition, CYLD(FF)xAlbCre mice showed a significantly increased sensitivity towards DEN/PB-induced hepatocarcinogenesis. Moreover, we could observe the development of cholangiocellular carcinoma, in line with enhanced oval cell activity. NF-κB-signaling was increased in livers of CYLD(FF)xAlbCre mice and likely contributed to the inflammatory and fibrotic response.
CONCLUSIONS: The deletion of exon7/8 of the CYLD gene activates oval cells, leads to a biliary phenotype, and increases the susceptibility towards carcinogenesis in the liver. Thus, our study presents a novel model of biliary damage and liver fibrosis, followed by cancer development.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728872     DOI: 10.1016/j.jhep.2012.06.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

1.  TNFα in liver fibrosis.

Authors:  Yoon Mee Yang; Ekihiro Seki
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

Review 2.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

3.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.

Authors:  Yan-Xiao Ji; Zan Huang; Xia Yang; Xiaozhan Wang; Ling-Ping Zhao; Pi-Xiao Wang; Xiao-Jing Zhang; Michele Alves-Bezerra; Lin Cai; Peng Zhang; Yue-Xin Lu; Lan Bai; Mao-Mao Gao; Huan Zhao; Song Tian; Yong Wang; Zhi-Xiang Huang; Xue-Yong Zhu; Yan Zhang; Jun Gong; Zhi-Gang She; Feng Li; David E Cohen; Hongliang Li
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

4.  Down-regulated cylindromatosis enhances NF-κB activation and aggravates inflammation in HBV-ACLF patients.

Authors:  Xueyun Zhang; Yao Zhang; Pu Zhou; Jingwen Ai; Xiaoqin Liu; Quanbao Zhang; Zhengxin Wang; Hongyan Wang; Wenhong Zhang; Jiming Zhang; Yuxian Huang
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

5.  CYLD deletion triggers nuclear factor-κB-signaling and increases cell death resistance in murine hepatocytes.

Authors:  Toni Urbanik; Bruno Christian Koehler; Laura Wolpert; Christin Elßner; Anna-Lena Scherr; Thomas Longerich; Nicole Kautz; Stefan Welte; Nadine Hövelmeyer; Dirk Jäger; Ari Waisman; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 6.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.

Authors:  Stefan Welte; Toni Urbanik; Christin Elßner; Nicole Kautz; Bruno Christian Koehler; Nina Waldburger; Justo Lorenzo Bermejo; Federico Pinna; Karl-Heinz Weiss; Peter Schemmer; Dirk Jaeger; Thomas Longerich; Kai Breuhahn; Henning Schulze-Bergkamen
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

8.  Bcl-xL is an oncogenic driver in colorectal cancer.

Authors:  Anna-Lena Scherr; Georg Gdynia; Mariam Salou; Praveen Radhakrishnan; Katarina Duglova; Anette Heller; Sophia Keim; Nicole Kautz; Adam Jassowicz; Christin Elssner; You-Wen He; Dirk Jaeger; Mathias Heikenwalder; Martin Schneider; Achim Weber; Wilfried Roth; Henning Schulze-Bergkamen; Bruno Christian Koehler
Journal:  Cell Death Dis       Date:  2016-08-18       Impact factor: 8.469

9.  CYLD Deubiquitinase Negatively Regulates High Glucose-Induced NF-κB Inflammatory Signaling in Mesangial Cells.

Authors:  Yanhui Li; Wei Huang; Youhua Xu; Luping Zhou; Yaling Liang; Chenlin Gao; Yang Long; Yong Xu
Journal:  Biomed Res Int       Date:  2017-11-12       Impact factor: 3.411

10.  Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.

Authors:  Bruno Christian Koehler; Anna-Lena Scherr; Stephan Lorenz; Christin Elssner; Nicole Kautz; Stefan Welte; Dirk Jaeger; Toni Urbanik; Henning Schulze-Bergkamen
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.